WaveMan
WaveMan · Company
IBO · Impact Biomedical Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

IBO Impact Biomedical (IBO) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001834105
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
6
13F, latest reported quarter

What the filings say about IBO

Insiders, 180 days
-$1.7K net sold
1 seller · 0% of sales under a 10b5-1 plan

Impact Biomedical insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, IMPACT BIOMEDICAL INC. insiders sold a net $1.7K of stock across 40 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
DSS, INC.
SELL
2026-09-24 SEC
156
$1.1K
-34.4%
Context
  • 20 earlier Form 4 trades (code P or S) here by this insider (4 buys, 16 sales), the last on Sep 23, 2026.
  • -9.4% median (-24.6% mean) 90-day return after 4 previous buys.
  • The trade is 0.0% of the 589,518 shares held after it.
  • No other insider sold within 30 days.
  • 6 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider DSS, INC. sold about $1.1K of IBO on Sep 24, 2026; 6 funds added in the latest 13F quarter.
DSS, INC.
SELL
2026-09-24 SECtraded 2026-09-23
27
$188
-34.4%
Context
  • 19 earlier Form 4 trades (code P or S) here by this insider (4 buys, 15 sales), the last on Sep 22, 2026.
  • -9.4% median (-24.6% mean) 90-day return after 4 previous buys.
  • The trade is 0.0% of the 589,674 shares held after it.
  • No other insider sold within 30 days.
  • 6 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider DSS, INC. sold about $188 of IBO on Sep 23, 2026; 6 funds added in the latest 13F quarter.
DSS, INC.
SELL
2026-09-24 SECtraded 2026-09-22
723
$398
-34.4%
Context
  • 18 earlier Form 4 trades (code P or S) here by this insider (4 buys, 14 sales), the last on May 27, 2025.
  • -9.4% median (-24.6% mean) 90-day return after 4 previous buys.
  • The trade is 0.1% of the 589,701 shares held after it.
  • No other insider sold within 30 days.
  • 6 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider DSS, INC. sold about $398 of IBO on Sep 22, 2026; 6 funds added in the latest 13F quarter.
Macko Todd D
Chief Financial Officer
SELL
2026-03-30 SECtraded 2026-03-27
43,400
$24.3K
+521.7%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Mar 25, 2026.
  • The trade is 28.0% of the 155,122 shares held after it.
  • 1 other insider sold within 30 days.
  • 6 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Macko Todd D sold about $24.3K of IBO on Mar 27, 2026; 1 other insider sold within 30 days and 6 funds added in the latest 13F quarter.
Macko Todd D
Chief Financial Officer
SELL
2026-03-30 SECtraded 2026-03-25
1,600
$960
+521.7%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 0.8% of the 198,122 shares held after it.
  • 1 other insider sold within 30 days.
  • 6 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Macko Todd D sold about $960 of IBO on Mar 25, 2026; 1 other insider sold within 30 days and 6 funds added in the latest 13F quarter.
40 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 35 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$1.7K over 180 days
-$1.7K over 90 days · -$1.7K of it by a 10%+ holder
more than 64% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
6 funds bought in last quarter
below 92% of Pharma & Biotech
Revenue
-36.0% year over year
below 75% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
3.3% of the float short (float per yahoo 2026-10-26) · 2.0 days to cover · settled 2026-09-30
below 92% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch IBO

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+538.7%12M
-31%+372%+775%+1179%2025-102025-122026-022026-042026-062026-082026-10 2026-03-23 · Grady Jason sold $32.5K2026-03-27 · Macko Todd D sold $24.3K2026-09-24 · DSS, INC. sold $1.1K2026-03-25 · Macko Todd D sold $9602026-09-22 · DSS, INC. sold $3982026-09-23 · DSS, INC. sold $188
Insider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns IBO: institutional holders (13F)

13F holdings, latest reported quarter
GEODE CAPITAL MANAGEMENT, LLC
1,185,163 sh
$545.6K
VANGUARD CAPITAL MANAGEMENT LLC
808,689 sh
$372.0K
STATE STREET CORP
607,897 sh
$279.6K
VANGUARD FIDUCIARY TRUST CO
589,428 sh
$271.1K
BlackRock, Inc.
259,946 sh
$119.6K

Congress trades in IBO

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

IBO planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

IBO mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$294.8K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$361.2K position · as of 2026-06-30
0.0%
Fidelity Total Market Index Fund
$123.2K position · as of 2026-05-31
0.0%
Total Stock Market Index Trust
$1.0K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$80.6K position · as of 2026-05-31
0.0%
iShares Core S&P Total U.S. Stock Market ETF
$3 position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $1.7K sold by insiders over 180 days, 6 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

IBO financials

Revenue growth
-36.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$35.0K
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
1.11x
current debt only, 2023-09-30 (33 months older than the period end); equity 2026-06-30
Cash flow to debt
-0.04x
TTM operating cash flow over current debt only, 2023-09-30 (33 months older than the period end)
Return on equity
+371.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+4.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-96.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
4.24x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
$414.1M
market value at close 2026-10-26 on 2026-08-04 shares, plus current debt only, 2023-09-30 (33 months older than the period end), minus cash 2026-03-31
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$32.0Kn/an/a$50.0K
Operating income-$4.3M-$28.8M-$4.0M-$3.4M
Net income-$11.8M-$24.7M-$4.3M-$7.3M
EPS (diluted)-0.38-2.30-0.07-0.10
Operating cash flow-$1.9M-$2.9M-$2.9M-$2.2M
Cash$3.0K$2.0M$1.0K$2.0K
SEC XBRL, fiscal years, as known on 2026-10-28

IBO Stock Sonar score 6/7 axes

Find similar shapesCompare

IBO ranks highest on profitability (70th percentile) and risk and compliance (66th), and lowest on institutional and government (8th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
70
Inputs
  • Return on equity+371.3% · 99 pct, sector of 545
  • Return on assets+4.4% · 85 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-96.5% · 27 pct, sector of 576
Financial health
44
Inputs
  • Debt to equity1.11x · 17 pct, sector of 352
  • Cash flow to debt-0.04x · 70 pct, sector of 371
Growth
25
Inputs
  • Revenue growth, YoY-36.0% · 25 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
31
Inputs
  • Net Form 4 buying (codes P and S), 180d-$2K · 63 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
8
Inputs
  • Funds adding, latest quarter6 · 8 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
66
Inputs
  • Short interest, % of float+3.3% · 66 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+7.7% · 66 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

IBO filings, in plain words

Are Impact Biomedical insiders buying or selling IBO?

In the 180 days to 2026-10-28, Impact Biomedical insiders were net sellers, a net $1.7K across purchases and sales reported on Form 4, by 1 seller.

Read the full summary

In the 180 days to 2026-10-28, Impact Biomedical insiders were net sellers of IBO, a net $1.7K across purchases and sales reported on Form 4 by 1 seller. Most of that figure, $1.7K, came from a holder of 10% or more rather than an officer or director. None of the 3 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies